Streetbeat News

Products Services

INTC

NVDA

SMCI

TSM

Intel and Sharp are collaborating to innovate chip production and cut costs by using Sharp's underutilized LCD plants in Japan. This partnership will help Intel focus on back-end chip production processes and provide Sharp with needed income. Nvidia is considering Intel as a potential supplier, while TSMC faces supply chain constraints and plans to hike prices. Intel aims to enhance its AI chip offerings, potentially generating significant revenue in 2024.

Portfolio Pulse from Anusuya Lahiri

June 06, 2024 | 2:11 pm

LIVN

LivaNova shares are trading lower after the company's RECOVER clinical study did not meet its primary endpoint for the unipolar cohort, though statistical significance was achieved in select secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:10 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo for June 6th, 2024, provides a detailed analysis of key price levels for SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA. The memo outlines potential bullish and bearish scenarios for each asset, emphasizing the importance of monitoring these levels closely. The memo also highlights the impact of the European Central Bank's rate decision and other economic data releases on market sentiment and volatility.

Portfolio Pulse from RIPS

June 06, 2024 | 2:10 pm

MAIA

MAIA Biotechnology has announced significant year-to-date achievements, including clinical progress of its lead candidate THIO, a first-in-class cancer telomere targeting agent for non-small cell lung cancer (NSCLC). The company has secured over $12 million in funding, with $7.4 million raised in Q2'24. THIO has shown exceptional efficacy in Phase 2 clinical trials, with a 38% overall response rate and a median progression-free survival of 5.5 months, outperforming current standard-of-care treatments.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:08 pm

BTCUSD

ETHUSD

RIOT

Bitcoin Spot ETFs have experienced 17 consecutive days of inflows, totaling $15.3 billion year-to-date. This trend indicates strong investor interest in Bitcoin ETFs. Additionally, Ethereum ETF inflows are expected to impact Bitcoin and cryptocurrency prices. Riot Platforms has increased its stake in Bitfarms to 12%, stirring up the Bitcoin mining market.

Portfolio Pulse from Akanksha Bakshi

June 06, 2024 | 2:06 pm

RTX

Raytheon Technologies has successfully established communication with CubeSats for NASA's PREFIRE mission, which aims to measure Earth's heat emission from the Arctic and Antarctica.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:01 pm

MRNA

The FDA has selected Moderna's investigational therapeutic mRNA-3705 for the START pilot program, which aims to accelerate the development of treatments for rare diseases. This selection will enhance communication with the FDA and expedite the development of mRNA-3705, which is being investigated for methylmalonic acidemia (MMA).

Portfolio Pulse from Vandana Singh

June 06, 2024 | 1:59 pm

ADDYY

LULU

NKE

Lululemon Athletica Inc. (NASDAQ:LULU) surpassed Wall Street’s earnings and revenue estimates for its first fiscal quarter but issued a weak second quarter outlook due to a slowdown in the Americas. Despite this, Lululemon's stock jumped 10% in extended trading. The company faces challenges with inventory and growth in its largest market but expects improvements in the second half of the year. Nike (NYSE: NKE) and Adidas AG (OTC: ADDYY) are also mentioned as competitors facing their own challenges.

Portfolio Pulse from Upwallstreet

June 06, 2024 | 1:54 pm

NASA's Boeing Crew Flight Test successfully rendezvoused and docked with the International Space Station (ISS) at approximately 12:15 p.m. EDT.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 1:53 pm

SGMT

Sagimet Biosciences Inc (NASDAQ:SGMT) presented promising data from its FASCINATE-2 Phase 2b clinical trial of denifanstat for MASH patients at the EASL Congress. The trial showed significant improvements in primary and secondary endpoints compared to placebo, with no serious adverse events reported.

Portfolio Pulse from Vandana Singh

June 06, 2024 | 1:52 pm